Document:

Exhibit 10.2

 

EXECUTION COPY

 

TETRALOGIC PHARMACEUTICALS CORPORATION

 

Debt Exchange

November 2, 2016

 

WHEREAS, concurrently with the execution of an asset purchase agreement (the “APA”) between TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Issuer”), and Medivir AB, a company organized under the laws of Sweden (“Medivir”), for the sale of substantially all of the Issuer’s assets relating to the birinapant and SHP-141 (remetinostat) lead molecules to Medivir (the “Medivir Sale”) and as a condition and inducement to its willingness to enter into the APA, the Company has requested that each Noteholder set forth in Schedule I hereto (each, a “Noteholder”) agree, and each of the Noteholders has agreed, to enter into this Term Sheet;

 

WHEREAS, each Noteholder signatory to this Term Sheet currently owns, beneficially or of record, the aggregate principal amount of 8.00% Convertible Senior Notes due 2019 (the “Notes”) of the Issuer set forth on Schedule I hereto next to such Noteholder’s name, and all rights to interest thereon;

 

WHEREAS, the Notes listed on Schedule I hereto collectively represent 100% of all issued and outstanding principal amount of the Notes on the date hereof;

 

WHEREAS, this Term Sheet will become effective only when agreed to, and executed, by holders of 100% in aggregate principal amount of Notes;

 

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises hereinafter set forth, the Company and each Noteholder hereby agree as follows:

 

	
Note Exchange
    	
 
    	
To the exchange (the “Exchange”) of $2,200,000 in aggregate principal amount of   issued and outstanding Notes (the “Aggregate Converted   Amount”) for 12,222,222 newly issued shares of convertible   participating preferred stock series A of the Issuer (the “Preferred Stock”), having a liquidation preference of   $0.18 per share of Preferred Stock (the “Liquidation Preference”).

 

Following the Exchange,   there will remain $41,550,000 in aggregate principal amount of Notes   outstanding (the “Remaining Notes”)   plus accrued but unpaid interest thereon. As of October 31, 2016, there   is $$1,322,222.49 of accrued and unpaid interest on the Notes.

 

The specific Aggregate   Converted Amount and Remaining Notes of each holder Notes will be as set   forth in Schedule I hereto.

 

Upon issuance of the   Preferred Stock, the Aggregate Converted 
    

 

 

	
 
    	
 
    	
Amount surrendered for   Exchange will be deemed paid in full and canceled.

 

As soon as practicable   following the date hereof and no later than November 14, 2016, the   Noteholders shall execute and deliver an Exchange and Consent Agreement (the   “Exchange and Consent Agreement”)   substantially in the form attached as Exhibit A hereto.
    
	
 
    	
 
    	
 
    
	
Remaining Notes
    	
 
    	
The Remaining Notes   will remain issued and outstanding in accordance with their terms and   governed by the indenture dated June 23, 2014 (the “Indenture”),   subject to such amendments and modifications as may be agreed upon by the   Noteholders as set forth in and evidenced by a supplemental indenture to   become effective on the date of closing of the Medivir Sale (see “Exchange   Timing and Mechanics / Supplemental Indenture” below).

 

Upon the consummation   of the Medivir Sale, $12,000,000 (the “Closing Cash Amount”)   shall be promptly distributed in cash to the holders of Remaining Notes in   partial redemption of $12,000,000 in aggregate principal amount of such   Remaining Notes and in priority to any payments to the holders of Preferred   Stock or Junior Stock (as defined below).
    
	
 
    	
 
    	
 
    
	
Restrictions on   Transfers of Remaining Notes
    	
 
    	
Until the consummation   of the Medivir Sale, holders of Remaining Notes shall not transfer, directly   or indirectly, any such Remaining Notes except to other persons who have   agreed to be bound by the terms set forth in this Term Sheet and in the   Exchange and Consent Agreement.
    
	
 
    	
 
    	
 
    
	
Preferred Dividends
    	
 
    	
The Preferred Stock   will entitle its holders to a preferred dividend when, as and if declared by   the board of directors of the Issuer (the “Board”),   at a rate of 8%. Dividends shall be cumulative, whether or not declared by   the Board and shall accrue semi-annually from the date of issuance of the   Preferred Stock or from the most recent date on which dividends were paid or   provided for.

 

Dividends on the   Preferred Stock shall be payable prior to and in preference to any payment of   any dividend or other distribution on stock which ranks junior to the   Preferred Stock, including the common stock (collectively, the “Junior Stock”). No dividends or other distributions shall   be made on Junior Stock prior to all payments on the Preferred Stock having   been made in full.

 

After all accrued but   unpaid dividends have been paid on the 
    

 

2

 

	
 
    	
 
    	
Preferred Stock, the   holders of Preferred Stock shall also be entitled to any additional dividends   or other distributions paid on the common stock by the Issuer in an amount   per share of Preferred Stock equal to the amount paid or distributed per   share of common stock as if the Preferred Stock had been converted into   common stock as provided under “Conversion Rights” below.
    
	
 
    	
 
    	
 
    
	
Liquidation Rights
    	
 
    	
Upon (i) a   liquidation, dissolution or winding-up of the Issuer, whether voluntary or   involuntary, (ii) a merger or consolidation of the Issuer, (iii) a   sale, lease or other transfer or disposition of all or substantially all of   the assets of the Issuer and/or its subsidiaries (including the Medivir Sale)   or (iv) a change of control or other direct or indirect transfer of the   Issuer’s securities such that after such transfer a person or group of   related persons (other than holders of Notes and their affiliates) would own   directly or indirectly 50% or more of the outstanding voting stock of the   Issuer (each, a “Liquidation Event”),   after (i) taking into account other costs of liquidation and after   (ii) all payments on the Remaining Notes have been made in full as   provided above, but before (iii) any payment or distribution is   made to the holders of Junior Stock, the holders of Preferred Stock shall be   entitled to receive out of the assets of the Issuer legally available for   distribution an amount per share of Preferred Stock equal to the sum of the   aggregate Liquidation Preference of the Preferred Stock plus any accrued but   unpaid dividends per share of Preferred Stock as provided under “Preferred   Dividends” above (the “Liquidation Amount”).

 

If, upon consummation   of such Liquidation Event, the assets of the Issuer and its subsidiaries are   insufficient to make payment in full of the Liquidation Amount to all holders   of Preferred Stock, then such assets shall be distributed pro rata among the   holders of Preferred Stock based on their respective Liquidation Amount.

 

If, in any Liquidation   Event, the amount of consideration received by the Issuer or its subsidiaries   in such Liquidation Event is in the form of milestone payments or earn-outs,   such amounts (net of costs of liquidation) shall be promptly distributed to   the holders of Preferred Stock as and when received by the Issuer or its   subsidiaries until the Liquidation Amount owed to such holders is paid in   full.

 

After the Liquidation   Amount has been paid in full on the 
    

 

3

 

	
 
    	
 
    	
Preferred Stock, the   holders of Preferred Stock shall also be entitled to any additional dividends   or other distributions paid on the common stock by the Issuer in an amount   per share equal to the amount paid or distributed per share of common stock   as if the Preferred Stock had been converted into common stock as provided   under “Conversion Rights” below.
    
	
 
    	
 
    	
 
    
	
Conversion Rights
    	
 
    	
Each outstanding share   of Preferred Stock shall be convertible at any time at the option of the   holder thereof and without payment of additional consideration into fully   paid and non-assessable shares of common stock. The number of shares of   common stock into which each share of Preferred Stock shall initially be   convertible (the “Conversion Ratio”)   into shall be shall be one (1).

 

The Conversion Ratio   shall be subject to customary adjustments for stock splits, dividends and   equity issuances.
    
	
 
    	
 
    	
 
    
	
Voting Rights
    	
 
    	
The holders of   Preferred Stock will vote on all matters submitted to a vote of the holders   of stock of the Issuer, including any vote submitted to a vote of the holders   of common stock of the Issuer, in which case they will hold the number of   votes equal to the number of shares of common stock into which such shares of   Preferred Stock would be converted into if converted as provided under   “Conversion Rights” above.
    
	
 
    	
 
    	
 
    
	
Redemption Rights
    	
 
    	
There will be no   redemption rights on the Preferred Stock.
    
	
 
    	
 
    	
 
    
	
Covenants
    	
 
    	
The Certificate of   Designations for the Preferred Stock will include restrictions on the ability   of the Issuer to do the following without consent of a majority of the issued   and outstanding shares of Preferred Stock:

 

·                  Consummate any Liquidation Event

·                  Incur any indebtedness

·                  Issue any Junior Stock or other   equity securities that would be pari passu or senior in right of payment,   upon liquidation or otherwise, to the Preferred Stock

·                  Enter into any contract for the   consummation of any event above

 

The Exchange and   Consent Agreement will also include restrictions on the ability of any holder   to transfer, directly or indirectly, its shares of Preferred Stock prior to   the consummation of the Medivir Sale except to other persons who have agreed   to be bound by the terms set forth in this Term Sheet and in the Exchange and   Consent Agreement.
    

 

4

 

	
Exchange Timing and   Mechanics / Supplemental Indenture
    	
 
    	
Each Noteholder hereby   agrees to: (i) the Exchange upon the individual terms set forth for each   such holder on Schedule I, (ii) the consummation of the Medivir   Sale (including voting their shares of Preferred Stock in favor of such   Medivir Sale), and (iii) the Company’s use of all the Closing Cash   Amount received from the Medivir Sale, to pay the outstanding amounts due   under the Remaining Notes in the first instance.

 

Each Noteholder further   conditionally agrees to (a) waive any put right for their Notes related   to the Medivir Sale or a delisting or suspension of trading of the Issuer’s   common stock, (b) waive any right to receive current cash payment of   interest on the Remaining Notes on the interest payment date under the   Indenture and agree that any interest will continue to accrue until paid,   (c) waive any public reporting and other rights under the Indenture, in   each case as may be necessary or advisable to give effect to the terms set   forth in this Term Sheet and in the Exchange and Consent Agreement,   (d) extend the maturity of the Remaining Notes until June 15, 2024,   and (e) to execute and/or deliver such other documents and agreements   and take such other actions as are customary and reasonably necessary to   effectuate the partial redemption of the Remaining Notes contemplated by this   Term Sheet, including consenting to any amendment or supplement to the   Indenture to permit such partial redemption. The waivers and extensions set   forth in clauses (a) through (e) above shall automatically   terminate and be of no further force and effect as if they had never been   provided if the APA is terminated or the Medivir Sale is not consummated for   any reason. Upon the closing of the Medivir Sale, the Noteholders and the   Company will enter into a supplement to the Indenture to permanently waive or   otherwise amend the Indenture to reflect the matters identified in clauses   (a) through (e) above.

 

Holders of Notes will   agree to withdraw the Aggregate Converted Amount of Notes from the facilities   of The Depository Trust Company and perform all acts requested by the Issuer   or its counsel in connection with the Exchange and other transactions   contemplated in this Term Sheet.
    
	
 
    	
 
    	
 
    
	
Timeline
    	
 
    	
The Exchange will be   consummated and the Preferred Stock issued as soon as practicable following   the execution of the Exchange and Consent Agreement and in any event prior to   the record date for the shareholders meeting for the approval of the Medivir   Sale.
    
	
 
    	
 
    	
 
    
	
Securities   Considerations
    	
 
    	
The Preferred Stock   will be issued in reliance on Section
    

 

5

 

	
 
    	
 
    	
4(a)(2) and   Regulation D under the Securities Act of 1933 and will be “restricted” upon   issuance.

 

The Issuer will delist   and deregister the common stock as soon as practicable following the   execution of the Exchange and Consent Agreement.
    
	
 
    	
 
    	
 
    
	
Other Unsecured   Liabilities
    	
 
    	
Other unsecured   liabilities of the Issuer shall be as set forth in the budget attached as Exhibit B   hereto and paid with cash on hand of the Issuer as and when they become   payable and in no event later than three (3) business days following the   closing of the Medivir Sale. In no event shall the Closing Cash Amount be   used by the Issuer to pay such unsecured liabilities. In no event shall the   holders of Notes take any action to restrict the payment by the Issuer of   such unsecured liabilities with the Issuer’s current available cash on hand.
    
	
 
    	
 
    	
 
    
	
Professional Fees
    	
 
    	
The Issuer shall pay   the reasonable and documented fees and expenses of one firm of counsel for   holders of Notes, related to the exchange of Note, issuance of the Preferred   Stock and other matters as set forth in this Term Sheet.
    
	
 
    	
 
    	
 
    
	
Governing Law
    	
 
    	
New York Law.
    

 

6

 

The Noteholders and the Company have caused their respective signature pages to this Term Sheet to be duly executed as of the date first written above.

 

	
 
    	
COMPANY
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
TETRALOGIC PHARMACEUTICALS CORPORATION
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ J. Kevin Buchi
    
	
 
    	
 
    	
Name: J. Kevin Buchi
    
	
 
    	
 
    	
Title: CEO
    

 

[Signature Page to Term Sheet for Note Exchange]

 

 

	
 
    	
NOTEHOLDERS
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
WHITEBOX RELATIVE VALUE PARTNERS L.P.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Mark Strefling
    
	
 
    	
 
    	
Name: Mark Strefling
    
	
 
    	
 
    	
Title:    Chief Operating Officer and General Counsel 
    

 

[Signature Page to Term Sheet for Note Exchange]

 

 

	
 
    	
NOTEHOLDERS
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
WHITEBOX MULTI-STRATEGY PARTNERS L.P.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Mark Strefling
    
	
 
    	
 
    	
Name: Mark Strefling
    
	
 
    	
 
    	
Title:    Chief Operating Officer and General Counsel 
    

 

[Signature Page to Term Sheet for Note Exchange]

 

 

	
 
    	
NOTEHOLDERS
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
PANDORA SELECT PARTNERS L.P.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Mark Strefling
    
	
 
    	
 
    	
Name: Mark Strefling
    
	
 
    	
 
    	
Title:    Chief Operating Officer and General Counsel 
    

 

[Signature Page to Term Sheet for Note Exchange]

 

 

	
 
    	
NOTEHOLDERS
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
WHITEBOX GT FUND L.P. 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Mark Strefling
    
	
 
    	
 
    	
Name: Mark Strefling
    
	
 
    	
 
    	
Title:    Chief Operating Officer and General Counsel 
    

 

[Signature Page to Term Sheet for Note Exchange]

 

 

	
 
    	
LAZARD ASSET MANAGEMENT LLC,

an investment adviser to certain accounts   and pooled investment vehicles it manages
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 /s/   Gerald B. Mazzari
    
	
 
    	
 
    	
Name: Gerald B. Mazzari
    
	
 
    	
 
    	
Title:     Chief Operating Officer 
    

 

[Signature Page to Term Sheet for Note Exchange]

 

 

	
 
    	
HIGHBRIDGE INTERNATIONAL LLC
    
	
 
    	
 
    
	
 
    	
By:    HIGHBRIDGE CAPITAL MANAGEMENT, LLC,

as Trading Manager
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 /s/   Jason Hempel 
    
	
 
    	
 
    	
Name:    Jason Hempel 
    
	
 
    	
 
    	
Title:     Managing Director 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
HIGHBRIDGE TACTICAL CREDIT &   CONVERTIBLES MASTER FUND, L.P. 
    
	
 
    	
 
    
	
 
    	
By:    HIGHBRIDGE CAPITAL MANAGEMENT, LLC,

as Trading Manager
    
	
 
    	
 
    
	
 
    	
By:
    	
 /s/   Jason Hempel 
    
	
 
    	
 
    	
Name:    Jason Hempel 
    
	
 
    	
 
    	
Title:     Managing Director 
    

 

[Signature Page to Term Sheet for Note Exchange]

 

 

	
 
    	
GEODE DIVERSIFIED FUND
    
	
 
    	
 
    
	
 
    	
BY: GEODE CAPITAL MANAGEMENT LP, manager 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 /s/   Jeffrey S. Miller 
    
	
 
    	
 
    	
Name: Jeffrey S. Miller 
    
	
 
    	
 
    	
Title: Chief Operating Officer 
    

 

[Signature Page to Term Sheet for Note Exchange]

 

 

	
 
    	
LINDEN ADVISORS LP
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 /s/   Robert G. Lennon
    
	
 
    	
 
    	
Name:    Robert G. Lennon
    
	
 
    	
 
    	
Title:    Director Legal Research/Analyst
    

 

[Signature Page to Term Sheet for Note Exchange]

 

 

	
 
    	
NOMURA SECURITIES INTERNATIONAL, INC.
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 /s/   Robert Thebault 
    
	
 
    	
 
    	
Name: Robert Thebault
    
	
 
    	
 
    	
Title:    Managing Director
    

 

[Signature Page to Term Sheet for Note Exchange]

 

 

	
 
    	
TELEMETRY SECURITIES LLC
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 /s/   Dan Sommers
    
	
 
    	
 
    	
Name:    Dan Sommers
    
	
 
    	
 
    	
Title: Portfolio Manager
    

 

[Signature Page to Term Sheet for Note Exchange]

 

 

	
 
    	
HUDSON BAY MASTER FUND LTD.
    
	
 
    	
 
    
	
 
    	
BY:    HUDSON BAY CAPITAL MANAGEMENT LTD. 
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Roy Astrachan 
    
	
 
    	
 
    	
Name:     Roy Astrachan
    
	
 
    	
 
    	
Title:    Authorized Signatory 
    

 

[Signature Page to Term Sheet for Note Exchange]

 

 

	
 
    	
STATE OF NEW JERSEY COMMON PENSION FUND D
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Christopher McDonough 
    
	
 
    	
 
    	
Name:     Christopher McDonough 
    
	
 
    	
 
    	
Title:     Director, Division of Investment 
    

 

[Signature Page to Term Sheet for Note Exchange]

 

 

EXHIBIT A

 

EXHIBIT A

 

Exchange and Consent Agreement

 

(See attached)

 

 

EXCHANGE AND CONSENT AGREEMENT

 

EXCHANGE AND CONSENT AGREEMENT (this “Agreement”), dated as of November   , 2016, by and between TetraLogic Pharmaceuticals Corporation, a Delaware corporation, with offices located at P.O. Box 1305, Paoli, PA 19301 (the “Company”), and each of the Noteholders listed on Schedule 1 attached hereto (collectively, the “Noteholders” and each individually, a “Noteholder”).

 

WHEREAS, the Company has agreed to sell substantially all of its assets relating to the birinapant and SHP-141 (remetinostat) lead molecules to Medivir AB, a company organized under the laws of Sweden (such transaction, the “Asset Purchase”), pursuant to the terms and conditions of that certain asset purchase agreement by and among the Company, its wholly-owned subsidiary TetraLogic Research and Development Corporation and Medivir AB, dated as of November 2, 2016  (the “APA”);

 

WHEREAS, on June 23, 2014, the Company issued 8.00% Convertible Senior Notes due 2019 (the “Notes”) to certain investors under an indenture, dated as of June 23, 2014 (the “Indenture”);

 

WHEREAS, each Noteholder currently owns, beneficially or of record, the aggregate principal amount of Notes set forth on Schedule 1 hereto next to such Noteholder’s name, and all rights to interest thereon;

 

WHEREAS, the Notes listed on Schedule 1 hereto collectively represent 100% of all issued and outstanding principal amount of the Notes on the date hereof;

 

WHEREAS, the Notes have accrued but unpaid interest as of October 31, 2016 in the amount of $1,322,222,49; and

 

WHEREAS, concurrently with the execution of the APA and as a condition and inducement to its willingness to enter into the APA, the Company has requested that the Noteholders agree, and each of the Noteholders has agreed, to enter into this Agreement;

 

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises hereinafter set forth, the Company and each Noteholder hereby agree as follows:

 

I.             EXCHANGE OF NOTES.

 

A.            Within three (3) business days of execution of this Agreement (the “Exchange Date”), each Noteholder hereby agrees to, and to direct its nominee to, exchange the aggregate principal amount of Notes set forth for each Noteholder next to such Noteholder’s name under Schedule 1 hereto (collectively, the “Exchanged Notes”) for newly issued shares of convertible participating preferred stock series A of the Company (the “Preferred Stock”), having the designations, rights and preferences set forth in the term sheet attached as Exhibit A hereto (the “Term Sheet”), in the amount of Preferred Stock for each Noteholder set forth for such Noteholder on Schedule 1 hereto (such shares, the “Exchange Shares”).

 

2

 

B.            The Exchange Shares will be issued in a transaction exempt from registration pursuant to Section 4(a)(2) and Regulation D of the Securities Act of 1933, as amended (the “Securities Act”), and will be deemed “restricted” under the Securities Act.

 

C.            Prior to the Exchange Date, the Company shall have caused a certificate of designation for the Exchange Shares (the “Certificate of Designation”) to be filed in the State of Delaware and to be in full force and effect.

 

D.            On the Exchange Date, each Noteholder shall deliver or cause to be delivered to the trustee under the Indenture (the “Trustee”) a Deposit/Withdrawal At Custodian (DWAC) instruction requesting to withdraw the Exchanged Notes from its account.

 

E.            On or prior to the Exchange Date, the Company shall deliver or cause to be delivered to the Trustee an officer’s certificate, certifying the CUSIP, the list of participants and corresponding participant numbers, the date of withdrawal, and the Exchanged Notes to be withdrawn from each participant’s account.

 

F.             Upon confirmation from the Trustee that (i) the Exchanged Notes have been withdrawn from each participant’s account as provided in Section 1.e above and (ii) the Exchanged Notes have been cancelled in accordance with the provisions of the Indenture, the Company shall cause its transfer agent (the “Transfer Agent”) to credit the number of Exchange Shares to which each Noteholder is entitled hereunder to each Noteholder’s or its designee’s account in accordance with the instructions set forth on Schedule 1 hereto, on the books and records of the Company kept by the Transfer Agent. Immediately upon such crediting, all Exchanged Notes shall have been deemed satisfied and discharged in their entirety and no longer outstanding, in force and in effect.

 

G.            Following consummation of the Note exchange provided in this Section 1, there will remain $41,550,000 in aggregate principal amount of Notes outstanding (the “Remaining Notes”) plus accrued but unpaid interest on all Notes (including the Exchanged Notes) from June 15, 2016 to the Exchange Date (the “Accrued Interest”).

 

H.            The Company represents and warrants that upon issuance as provided hereunder and under the Certificate of Designation, all Exchange Shares will be validly issued, fully paid and non-assessable.

 

I.             The Company and each Noteholder shall execute and/or deliver such other documents and agreements as are mutually acceptable and take such other actions as are customary and reasonably necessary and mutually acceptable to effectuate the exchange of the Exchanged Notes and issuance of the Exchange Shares under this Section 1.

 

II.            REMAINING NOTES.

 

A.            As soon as practicable following the closing of the Asset Purchase and other transactions contemplated by the APA (the “APA Closing”), the Company shall pay $12,000,000  in cash (the “Closing Cash Amount”) to the Trustee as paying agent under the Indenture for the benefit of the holders of the Remaining Notes in partial redemption of $12,000,000 in aggregate principal amount of such Remaining Notes (the “Redeemed Notes”) prior to any other payments

 

3

 

to the holders of Preferred Stock or Junior Stock (as defined in the Certificate of Designation). Immediately upon such payment, all such redeemed aggregate principal amount of the Redeemed Notes shall be deemed satisfied and discharged in its entirety and no longer outstanding, in force and in effect.

 

B.            The Company shall deliver or cause to be delivered to the Trustee all notices, legal opinions and other officer’s certificates, and shall execute such supplemental indenture as may be necessary to effectuate such partial redemption of the Remaining Notes under the Indenture.

 

C.            The Company and each Noteholder shall execute and/or deliver such other documents and agreements as are mutually acceptable and take such other actions as are customary, reasonably necessary and mutually acceptable to effectuate the partial redemption of the Remaining Notes contemplated by this Agreement, including consenting to any amendments to the Indenture or the entry into of a supplemental indenture to permit such partial redemption.

 

III.          CONSENT AND VOTING.

 

A.            Each Noteholder hereby agrees to vote, or cause to be voted, all shares of Preferred Stock and all shares of Common Stock owned by such Noteholder or its affiliates, beneficially or of record, or over which such Noteholder or its affiliates have voting control, at any meeting of shareholders or pursuant to any action by written consent of the shareholders of the Company in favor of the Asset Purchase and the consummation of all transactions contemplated by the APA and related documentation.

 

B.            Each Noteholder hereby consents, and agrees to instruct the Trustee to consent, to the Asset Purchase and the consummation of all transactions contemplated by the APA and related documentation.

 

C.            The Company hereby agrees that it shall not enter into any amendment or provide any waiver under the APA without the prior consent of the Noteholders holding, of record, a majority in aggregate principal amount of the Notes then outstanding, which consent shall not be unreasonably withheld, conditioned or delayed.

 

IV.          ACKNOWLEDGEMENT AND WAIVERS.

 

A.            From and after the consummation of the Note exchange provided under Section 1 above and receipt by each Noteholder of the Exchange Shares hereunder, each Noteholder hereby acknowledges and agrees that:

 

(i) all amounts due and owing under such Noteholder’s Exchanged Notes shall have been satisfied in full except for the Accrued Interest and that there shall be no other amounts due or owing under such Exchanged Notes or the Indenture with respect to such Exchanged Notes except for the Accrued Interest;

 

(ii) all obligations other than the obligation to pay Accrued Interest under such Noteholder’s Exchanged Notes and the Indenture with respect to such Exchanged Notes shall have been fully satisfied and discharged; and

 

4

 

(iii) it waives any and all rights, title and interests under its Exchanged Notes and under the Indenture with respect to such Exchanged Notes, including without limitation its right to receive any payment of principal or any other amount (other than the Accrued Interest) under such Exchanged Notes.

 

B.            From and after payment by the Company of the Closing Cash Amount, as contemplated in Section 2.a above, each Noteholder hereby acknowledges and agrees that:

 

(i) all amounts due and owing under the Redeemed Notes shall have been paid in full except for the Accrued Interest and all accrued but unpaid interest on the Remaining Notes from the Exchange Date to the date the Company paid the Closing Cash Amount as provided in Section 2 above (the “Remaining Interest” and, together with the Accrued Interest, the “Interest”) and that there shall be no other amounts due or owing under such Noteholder’s Redeemed Notes or the Indenture with respect to such Redeemed Notes other than the Interest; and

 

(ii) all obligations other than the obligation to pay Interest under such Noteholder’s Redeemed Notes and the Indenture with respect to such Redeemed Notes shall have been fully satisfied and discharged.

 

C.            From and after the date hereof, each Noteholder hereby conditionally waives with respect to any and all Notes owned by it and its affiliates, beneficially or of record, and agrees to cause its respective nominee(s) as record holder of any Note beneficially owned by it or its affiliates to waive:

 

(i) its right to exercise its right to put its Notes under Article 3 of the Indenture upon the occurrence of any event set forth under clauses (2) and (4) of the definition of Fundamental Change under the Indenture;

 

(ii) the applicability of the covenants and obligations set forth under Section 5.02 of the Indenture;

 

(iii) the applicability of the covenants and obligations set forth in Article 6 of the Indenture with respect to the Asset Purchase;

 

(iv) its rights to receive interest payments in cash under Section 12.01 of the Indenture on June 15 and December 15 of each year and agrees instead that any such interest amounts shall be paid through the issuance of additional notes having the same terms as the Remaining Notes as modified by this Agreement; and

 

(v) the applicability of any defined terms or Events of Default (as defined in the Indenture) or other terms or covenants under the Indenture related to the waivers set forth above.

 

D.            Each Noteholder hereby conditionally agrees to extend with respect to any and all Remaining Notes owned by it and its affiliates, beneficially or of record, and agrees to cause its respective nominee(s) as record holder of any Remaining Note beneficially owned by it or its affiliates to extend, the maturity of the Remaining Notes to June 15, 2024.

 

5

 

E.            In addition, from and after the date hereof, each Noteholder hereby acknowledges and agrees not to declare, or instruct the Trustee to declare, an Event of Default (as defined in the Indenture) or accelerate the payment of any Notes owned by it and its affiliates, beneficially or of record, or to otherwise exercise or instruct the Trustee to exercise any remedy under the Indenture arising from any Event of Default, whether now existing or hereafter arising, until the consummation of the Asset Purchase and other transactions contemplated under the APA or termination of the APA by one or both of the parties thereto in accordance with its terms, in each case, to the extent necessary for the consummation of the Asset Purchase and other transactions contemplated under the APA.

 

F.             The Company shall deliver or cause to be delivered to the Trustee all notices, legal opinions and other officer’s certificates, and shall execute such supplemental indenture as may be necessary to effectuate the waivers and amendments contemplated by this Section 4 to the Indenture.

 

G.            The Company and each Noteholder shall execute and/or deliver such other documents and agreements and take such other actions as are customary, reasonably necessary and mutually acceptable to effectuate the waivers and amendments contemplated by this Section 4, including consenting to any amendments to the Indenture or the entry into of a supplemental indenture to permit the partial redemption of the Remaining Notes.

 

V.            REPRESENTATIONS AND WARRANTIES

 

A.            Noteholder Representations and Warranties.  Each Noteholder, severally and not jointly, hereby represents and warrants to the Company that, as of the date hereof, as of the Exchange Date and as of the APA Closing:

 

1.             Such Noteholder has all necessary power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby.  The execution and delivery of this Agreement by such Noteholder and the consummation by such Noteholder of the transactions contemplated hereby have been duly and validly authorized by its board of directors or other governing body, and no other proceedings on its part are necessary to authorize this Agreement or to consummate such transactions.  This Agreement has been duly and validly executed and delivered by such Noteholder and, assuming due authorization, execution and delivery by the other parties hereto, constitutes its legal, valid and binding obligation, enforceable against such Noteholder in accordance with its terms, except to the extent enforceability may be limited by bankruptcy, insolvency, moratorium or other similar laws affecting creditors’ rights generally or by general principles governing the availability of equitable remedies, and, in the case of Common Pension Fund D, subject to the New Jersey Tort Claims Act (N.J.S.A. 59:1-1 et seq.) and the New Jersey Contractual Liability Act (N.J.S.A. 59:13-1 et seq.) as each may be amended from time to time.

 

2.             The execution and delivery of this Agreement by such Noteholder does not, and the performance of this Agreement by such Noteholder shall not, (A) conflict with or violate its organizational documents, (B) conflict with or violate any agreement, arrangement, law, rule, regulation, order, judgment or decree to which it is a party or by which it is (or the Notes or Preferred Stock owned, beneficially or of record, by it and its affiliates are) bound or

 

6

 

affected or (C) result in the creation of a lien or encumbrance on any of the Notes or Preferred Stock owned, beneficially or of record, by it and its affiliates which would affect such Noteholder’s ability to comply with the terms and conditions of this Agreement.

 

3.             The execution and delivery of this Agreement by such Noteholder does not, and the performance of this Agreement by such Noteholder shall not, require any consent, approval, authorization or permit of, or filing with or notification to, any governmental entity except for applicable requirements, if any, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

4.             Such Noteholder is the beneficial owner or owner of record of the Notes and will transfer and deliver to the Company as and when required under this Agreement valid title to the Exchanged Notes and the Redeemed Notes, each free and clear of all security interests, liens, claims, pledges, options, rights of first refusal, preemptive or similar rights, agreements, limitations on such Noteholder’s voting rights, charges and other encumbrances of any nature whatsoever.

 

5.             Such Noteholder shall receive the Exchange Shares under this Agreement for its own account solely for the purpose of investment and not with a view to, or for offer or sale in connection with, any distribution of the Exchange Shares in violation of the Securities Act and the rules and regulations promulgated thereunder.  Such Noteholder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of an investment in the Exchange Shares, and is able to bear the economic risk of such investment.

 

6.             Such Noteholder is a qualified institutional buyer as defined in Rule 144A under the Securities Act or an accredited investor as defined in Rule 501(a) of the Securities Act.

 

7.             Neither such Noteholder nor any of its affiliates or representatives has acted on behalf of the Company or has received any commission or remuneration from the Company in connection with entering into this Agreement or the consummation of the transactions contemplated under this Agreement or the APA.  Neither such Noteholder nor any of its affiliates or representatives (i) was solicited by any person or entity on behalf of the Company to enter into this Agreement or to consummate the transactions contemplated under this Agreement, or (ii) has solicited any other investor in the Company’s Notes to enter into this Agreement or to consummate the transactions contemplated under this Agreement.

 

B.            Company Representations and Warranties.  The Company hereby represents and warrants to such Noteholder that, as of the date hereof, as of the Exchange Date and as of the APA Closing:

 

1.             The Company has all necessary power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby.  The execution and delivery of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby have been duly and validly authorized by its board of directors or other governing body, and no other proceedings on its part are necessary to authorize this Agreement or to consummate such transactions.  This Agreement has been duly and validly executed and delivered by the Company and, assuming due

 

7

 

authorization, execution and delivery by the other parties hereto, constitutes its legal, valid and binding obligation, enforceable against the Company in accordance with its terms, except to the extent enforceability may be limited by bankruptcy, insolvency, moratorium or other similar laws affecting creditors’ rights generally or by general principles governing the availability of equitable remedies.

 

2.             The transactions contemplated by this Agreement, including the issuance of the Exchange Shares are duly authorized and upon issuance in accordance with the terms of this Agreement, the Exchange Shares will be validly issued, fully paid and non-assessable and free from all preemptive or similar rights, taxes, liens, charges and other encumbrances with respect to the issue thereof.

 

3.             The execution and delivery of this Agreement by the Company does not, and the performance of this Agreement by the Company shall not, (A) conflict with or violate its organizational documents, or (B) conflict with or violate any agreement, arrangement, law, rule, regulation, order, judgment or decree to which it is a party or by which it is bound or affected.

 

4.             The execution and delivery of this Agreement by the Company does not, and the performance of this Agreement by the Company shall not, require any consent, approval, authorization or permit of, or filing with or notification to, any governmental entity except as contemplated in this Agreement, or for applicable requirements, if any, of the Exchange Act, and except where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, would not prevent or delay the performance by the Company of its obligations under this Agreement.

 

VI.          COVENANTS.

 

A.            No Transfer.  Each Noteholder acknowledges and agrees prior to (i) the APA Closing and partial redemption of the Remaining Notes pursuant to Section 2.a of this Agreement or (ii) termination of the APA by either party thereto, not to, and to cause its respective affiliates and nominee(s) as record holder of any Note(s) beneficially owned by it or its affiliates not to, dispose or attempt to dispose, directly or indirectly, by operation of law or otherwise, voluntarily or involuntarily, of any Notes or shares of Preferred Stock owned by it or its affiliates, beneficially or of record, or any right, power, or interest therein, including through any sale, gift, pledge, encumbrance, or creation of a security interest in any Notes or shares of Preferred Stock; provided, that such Noteholder shall be permitted to transfer its interest in any Notes or shares of Preferred Stock to a party that agrees in writing to be bound by the terms and conditions of this Agreement and executes a joinder to this Agreement to that effect.  Each Noteholder hereby agrees and consents to the entry of stop transfer instructions by the Company with the Transfer Agent or the Trustee against the transfer of any Notes or shares of Preferred Stock inconsistent with the terms of this Section 6.a.

 

B.            Compliance with the Securities Act.  Each Noteholder acknowledges and agrees that (i) the Exchange Shares have not been and will not be registered under the Securities Act or any applicable securities laws of any state of the United States and that the sale contemplated hereby is being made in reliance on an exemption from such registration pursuant to Section 4(a)(2) and Regulation D of the Securities Act, and the Company is relying upon the truth and

 

8

 

accuracy of, and such Noteholder’s compliance with, the representations, warranties, covenants, agreements, acknowledgments and understandings of such Noteholder contained in this Agreement in order to determine the availability of such exemptions and eligibility of Noteholders to acquire the Exchange Shares; (ii) the Exchange Shares must be held indefinitely unless a subsequent disposition thereof is registered under the Securities Act or exempt from such registration; and (iii) the Exchange Shares will bear a legend substantially in the form set forth in Section 6.c below.

 

C.            Legend.

 

1.             It is understood that certificates evidencing the Exchange Shares may bear the following or any similar legend:

 

a.             “THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT AND SUCH REGISTRATION STATEMENT REMAINS EFFECTIVE, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, OR (III) IF REQUESTED BY THE COMPANY, THE COMPANY HAS RECEIVED AN OPINION OF COMPANY COUNSEL, STATING THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT.”

 

b.             “THE SECURITIES REPRESENTED HEREBY ARE SUBJECT TO TRANSFER RESTRICTIONS SET FORTH UNDER AN EXCHANGE AND CONSENT AGREEMENT DATED NOVEMBER   , 2016.  COPIES OF THIS AGREEMENT CAN BE OBTAINED FROM THE COMPANY UPON REQUEST.”

 

2.             If required by the authorities of any state of the United States in connection with the issuance of the Exchange Shares, the certificates evidencing the Exchange Shares will bear the legend required by such state authority.

 

VII.         TERMINATION.   In the event that (i) the APA is terminated for any reason, (ii) the Asset Purchase and other transactions contemplated under the APA are not consummated on or before January 31, 2017, or (iii) the Company announces its intent to pursue a transaction or a series of transactions alternative to the Asset Purchase and other transactions contemplated under the APA, then all waivers, agreements and covenants of the Noteholders set forth in Section 4.c, Section 4.d, Section 4.e and Section 6.a will immediately and automatically expire and will have no further force and effect.

 

VIII.       MISCELLANEOUS.

 

A.            Permission to Disclose.  Each Noteholder hereby agrees and consents to the disclosure by the Company of this Agreement and all transactions contemplated hereunder as required by law, including stock exchange and securities regulations (including on a Form 8-K or

 

9

 

proxy statement filed with the Securities and Exchange Commission).  For the avoidance of doubt, any such disclosure shall not identify any Noteholder by name.

 

B.            Specific Performance.  The parties hereto agree that irreparable damage may occur in the event any provision of this Agreement was not performed in accordance with the terms hereof and that the parties hereto shall be entitled to seek specific performance of the terms hereof, in addition to any other remedy at law or in equity.

 

C.            Entire Agreement.  This Agreement constitutes the entire agreement between the Company and each Noteholder with respect to the subject matter hereof and supersedes all prior agreements and understandings, both written and oral, between the Company and each Noteholder with respect to the subject matter hereof.

 

D.            Amendment.  This Agreement may not be amended and no other actions may be taken under this Agreement except by an instrument in writing signed by the Company and each Noteholder.

 

E.            Severability.  If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule or law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of this Agreement is not affected in any manner materially adverse to any party.  Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereby shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties hereto as closely as possible to the fullest extent permitted by applicable law in a mutually acceptable manner in order that the terms of this Agreement remain as originally contemplated.

 

F.             Notices.  All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed to have been duly given or made and shall be effective upon receipt if delivered personally, upon receipt of a transmission confirmation if sent by electronic transmission or facsimile (with a confirming copy sent by overnight courier) and on the next business day if sent by Federal Express, United Parcel Service, Express Mail or other reputable overnight courier to the parties at the following addresses (or at such other address for a party as shall be specified by notice), it being understood and agreed that with respect to Common Pension Fund D, all notices and communications will be made by personal delivery:

 

If to the Noteholder, to the address specified on Schedule 1 hereto.  With a copy to (which shall not constitute notice):

 

Brown Rudnick LLP

7 Times Square
 New York, NY 10036

Attention: John Storz

Facsimile: (212) 938-2825

E-mail: jstorz@brownrudnick.com

 

If to the Company, to:

 

TetraLogic Pharmaceuticals Corporation

 

10

 

P.O. Box 1305

Paoli, PA 19301

Telephone: (610) 889-9900

Fax: (610) 889-9994

Attention: General Counsel

 

with a copy to (which shall not constitute notice):

 

Pepper Hamilton LLP

400 Berwyn Park

899 Cassatt Road

Berwyn, PA 19312-1183

Telephone: (610) 640-7825

Fax: (610) 640-7835

Attention: Jeffrey P. Libson, Esq.

 

G.            Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be performed entirely within such state without regard to the principles of conflicts of law of any jurisdiction; provided that, solely with respect to Common Pension Fund D, this Agreement shall be governed by and construed in accordance with the laws of the State of New Jersey without regard to the principles of conflicts of law of any jurisdiction.

 

H.            MUTUAL WAIVER OF JURY TRIAL.  BECAUSE DISPUTES ARISING IN CONNECTION WITH COMPLEX TRANSACTIONS ARE MOST QUICKLY AND ECONOMICALLY RESOLVED BY AN EXPERIENCED AND EXPERT PERSON AND THE PARTIES WISH APPLICABLE STATE AND FEDERAL LAWS TO APPLY (RATHER THAN ARBITRATION RULES), THE PARTIES DESIRE THAT THEIR DISPUTES BE RESOLVED BY A JUDGE APPLYING SUCH APPLICABLE LAWS.  THEREFORE, EACH PARTY TO THIS AGREEMENT HEREBY WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE BETWEEN OR AMONG ANY OF THE PARTIES HERETO, WHETHER ARISING IN CONTRACT, TORT, OR OTHERWISE, ARISING OUT OF, CONNECTED WITH, RELATED OR INCIDENTAL TO THIS AGREEMENT AND/OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

I.             Consent to Jurisdiction.

 

1.             Each party to this Agreement, except the Common Pension Fund D:  (i) hereby irrevocably submits to the exclusive jurisdiction of the United States courts and New York State courts sitting in Manhattan, New York City, State of New York, for the purposes of any suit, action or proceeding arising out of or related to this Agreement and (ii) hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such courts, that the suit action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.  Each party hereto consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing

 

11

 

in this Section 8.i. shall affect or limit any right to serve process in any other manner permitted by law.

 

2.             Solely with respect to Common Pension Fund D, litigation related to this Agreement shall be bought in the appropriate courts of the State of New Jersey, and each of the Company and Common Pension Fund D, for purpose of any such litigation, hereby submits to the exclusive jurisdiction and venue of such courts.

 

J.             Counterparts.  This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which, when taken together, shall constitute one and the same instrument.  Delivery of an executed counterpart of a signature page by facsimile or other electronic transmission (including .pdf) shall be as effective as delivery of a manually executed counterpart.

 

K.            Fees and Expenses.  Each party shall bear its own expenses, including the fees and expenses of accountants, financial or other advisors or representatives engaged by it, incurred in connection with this Agreement and the transactions contemplated hereby; provided that the Company shall pay the reasonable and documented fees and expenses of one firm of counsel for all Noteholders related to this Agreement, the Certificate of Designation, the issuance of the Preferred Stock and other matters set forth in this Agreement.

 

L.            Survival of Representations, Warranties and Covenants.  The representations and warranties contained in or made pursuant to this Agreement shall survive the closing of the transactions contemplated hereunder without limitation.

 

M.           Successors and Assigns.  The provisions of this Agreement shall inure to the benefit of, and be binding upon, the parties hereto and their respective successors or assigns.

 

[Signature Pages Follow]

 

12EXHIBIT 10.3

 

EXECUTION VERSION

 

VOTING AGREEMENT

 

THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of November 2, 2016, by and among TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Company”), and each of the undersigned stockholders (each, a “Stockholder” and collectively, the “Stockholders”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), (the Company, and the Stockholders are hereby referred to individually, as a “Party”, and collectively, as the “Parties”).

 

R E C I T A L S

 

WHEREAS, each Stockholder is the owner, beneficially or of record, of such number of shares of Common Stock of the Company (the “Shares”) set forth on its signature page below;

 

WHEREAS, the Company is entering into an Asset Purchase Agreement, dated November 2, 2016 (the “APA”), with its wholly-owned subsidiary TetraLogic Research and Development Corporation, a Delaware corporation (“TR&D”), and Medivir AB, a company organized under the laws of Sweden (“Medivir”), pursuant to which Medivir will purchase substantially all of the assets of the Company and TR&D relating to the birinapant and SHP-141 (remetinostat) lead molecules (the “Asset Purchase”);

 

WHEREAS, the Board of Directors of the Company has: (x) determined that the Asset Purchase and APA are fair to, and in the best interests of, the Company and its stockholders; (y) approved the Asset Purchase and APA; and (z) determined to recommend to the stockholders of the Company to approve the Asset Purchase and the APA;

 

WHEREAS, as a condition to the willingness of Medivir to enter into the APA, Medivir has requested that each Stockholder agrees, and in order to induce Medivir to enter into the APA, each Stockholder has agreed, to enter into this Agreement in connection with the Asset Purchase.

 

NOW, THEREFORE, in consideration of the foregoing and of the mutual promises, covenants, representations, warranties, releases and agreements herein contained, and intending to be legally bound, the Parties hereby agree as follows:

 

A G R E E M E N T

 

1.             Representations of Stockholder.  Each Stockholder hereby represents and warrants, only with respect to itself, the following:

 

1

 

(a)           Such Stockholder owns, beneficially or of record, the Shares set forth on its signature page below, free and clear any liens, encumbrances, claims, pledges, impositions or defects in title.

 

(b)           Such Stockholder has the right to vote the number of Shares set forth below to its signature below.

 

(c)           Such Stockholder has full power and authority to enter into and preform all of such Stockholder’s obligations under this Agreement.  This Agreement has been duly executed and delivered by such Stockholder and, upon its execution and delivery by the Company, will constitute a legal, valid and binding obligation of such Stockholder, enforceable against such Stockholder in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting or relating to creditors rights generally, and the availability of injunctive relief and other equitable remedies.

 

(d)           Such Stockholder does not own, beneficially or of record, any equity or other ownership interest of the Company other than the Shares.

 

(e)           There are no options, warrants, voting, proxy, power of attorney or other rights, agreements, arrangements or commitments of any character to which such Stockholder is a party relating to the pledge, disposition or voting of any of the Shares and there are no voting trusts or voting agreements with respect to the Shares.

 

(f)            The execution and delivery of this Agreement by such Stockholder, the consummation by such Stockholder of the transactions contemplated hereby or compliance by such Stockholder with any of the provisions hereof will not (i) conflict with or result in a breach, or constitute a default (with or without notice of lapse of time or both) under any provision of, any contract or other agreement or obligation to which such Stockholder or to such Stockholder’s properties or assets may be bound; or (ii) violate any order, writ injunction, decree, judgment, order, law, statute, rule or regulation applicable to such Stockholder or any of such Stockholder’s assets or properties.

 

2.             Adjustments; Additional Shares.  In the event that after the date of this Agreement any shares of Common Stock or other securities of the Company or another corporation or other legal entity are issued with respect to, or in exchange for, any of the Shares by reason of any stock dividend, stock split, consolidation of shares, reclassification, recapitalization, exchange, merger or consolidation or otherwise involving the Company, such shares of Common Stock or other securities shall be deemed to be Shares for purposes of this Agreement.  Each Stockholder agrees that all shares of Common Stock or other securities of the Company that such Stockholder purchases, acquires the rights to vote or otherwise acquires beneficial ownership of after the execution of this Agreement, but during the term of this Agreement, shall be subject to the terms of this Agreement and shall constitute “Shares” for the purposes of this Agreement.

 

2

 

3.             Voting of Shares; Irrevocable Proxy.

 

(a)           During the term of this Agreement, and solely with respect to voting on the matters described in Section 3(b) below, each Stockholder agrees not to, and it shall not permit any entity under its control to, deposit any of the Shares in a voting trust, grant any proxies with respect to the Shares, grant any power of attorney with respect to the Shares or subject any of the Shares to any arrangement with respect to the voting of the Shares other than agreements entered into with the Company or Medivir. For the avoidance of doubt, this Agreement and the proxies and powers of attorney created hereby shall not apply to any matters submitted to the stockholders of the Company other than the matters described in Section 3(b) below.

 

(b)           Each Stockholder agrees during the term of this Agreement to vote the Shares, and to cause any holder of record of the Shares to vote or execute a written consent or consents if stockholders of the Company are requested to vote their shares through the execution of an action by written consent in lieu of any such annual or special meeting of stockholders of the Company: (i) in favor of the Asset Purchase and the APA, at every meeting (or in connection with any action by written consent) of the stockholders of the Company at which such matters are considered and at every adjournment or postponement thereof; and (ii) against (1) any action, proposal, transaction or agreement which would result in a breach of any covenant, representation or warranty or any other obligation or agreement of the Company under the APA or any other agreement related to the Asset Purchase, or of the Stockholders under this Agreement and (2) any action, proposal, transaction or agreement that would impede, interfere with, delay, discourage, adversely affect or inhibit the timely consummation of the Asset Purchase or the fulfillment of any conditions under this Agreement, the APA or any definitive agreements for the Asset Purchase or change in any manner the voting rights of any class of shares of the Company (including any amendments to the Company’s charter documents and by-laws).

 

(c)           Each Stockholder hereby appoints the Company and any designee of the Company, and each of them individually, its proxies and attorneys-in-fact, with full power of substitution and re-substitution, to vote or act by written consent during the term of this Agreement with respect to the Shares in accordance with this Section 3.  This proxy and power of attorney is given to secure the performance of the duties of each Stockholder under this Agreement.  Each Stockholder shall take such further action or execute such other instruments as may be necessary to effectuate the intent of this proxy. This proxy and power of attorney granted by each Stockholder shall be irrevocable during the term of this Agreement, shall be deemed to be coupled with an interest sufficient in law to support an irrevocable proxy and shall revoke any and all prior proxies granted by such Stockholder with respect to the Shares. The power of attorney granted by each Stockholder herein is a durable power of attorney and shall survive the dissolution, voluntary or involuntary bankruptcy, death or incapacity of such Stockholder. The proxy and power of attorney granted hereunder shall terminate upon the termination of this Agreement.

 

(d)           The Company hereby accepts its appointment as proxy of the Stockholders, pursuant to paragraph (c) of this Section 3.

 

3

 

4.             Transfer Restrictions.  Each Stockholder covenants and agrees for the benefit of the Company that, during the term of this Agreement, such Stockholder shall not:

 

(a)           sell, transfer, pledge, hypothecate, encumber, assign, tender or otherwise dispose of, or enter into any contract, option or other arrangement or understanding with respect to the sale, transfer, pledge, hypothecation, encumbrance, assignment, tender or other disposition of, any Shares or any interest therein; provided, however, such Stockholder may sell, transfer, pledge, hypothecate, encumber, assign, tender or otherwise dispose of any Shares to a family member or trust or other entity for estate or tax planning purposes, provided, that any such sale transfer, pledge, hypothecation, encumbrance, assignment, tender or other disposition shall be conditioned on each such transferee signing and delivering a Voting Agreement in substantially the form of this Agreement;

 

(b)           grant any powers of attorney or proxies or consents in respect of any of the Shares, deposit any of such Shares into a voting trust, or enter into a voting agreement with respect to any of such Shares; or

 

(c)           take any other action with respect to the Shares that would restrict, limit or interfere with the performance of such Stockholder’s obligations hereunder or the transactions contemplated hereby and by the APA.

 

5.             Term and Termination.  This Agreement and the proxies and powers of attorney provided shall terminate with respect to each Share, on a Share by Share basis, upon the earliest of (a) the mutual termination by the Parties, (b) the termination of the APA in accordance with its terms or (c) upon consummation of the transactions contemplated by the APA.

 

6.             Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to any conflict of law rule or principle that would give effect to the laws of another jurisdiction.

 

7.             Waiver of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 7.

 

4

 

8.             Benefits; Binding Effect.  This Agreement shall be for the benefit of and binding upon the Parties and their respective heirs, personal representatives, legal representatives, successors, assigns and transferees, as applicable.

 

9.             Amendment or Modification.  This Agreement may be altered, modified or amended only by the unanimous written consent of the Parties.

 

10.          Assignment.  No Party may assign either this Agreement or any of its rights, interests, or obligations hereunder without the prior written approval of the other Parties.

 

11.          Entire Agreement; Third Party Beneficiaries.  This Agreement constitutes the entire agreement among the Parties with respect to the subject matter hereof and supersedes all prior agreements, understandings and arrangements, both oral and written, among the Parties with respect to such subject matter.  This Agreement is not intended to confer any rights or remedies upon any person other than Medivir, which shall be deemed an express third party beneficiary of this Agreement, and the Parties.

 

12.          Specific Performance.  Each of the Parties agrees that this Agreement is intended to be legally binding and specifically enforceable pursuant to its terms and that the Company, would be irreparably harmed if any of the provisions of this Agreement are not performed in accordance with their specific terms and that monetary damages would not provide adequate remedy in such event.  Accordingly, in addition to any other remedy to which a non-breaching Party may be entitled at law, a non-breaching Party shall be entitled to injunctive relief without the posting of any bond to prevent breaches of this Agreement and to specifically enforce the terms and provisions hereof.  Each Party further waives (a) any defense that a remedy at law would be adequate in any action for specific performance or injunctive relief hereunder and (b) any requirement for the posting of a bond or other security as a condition to such relief.

 

13.          Severability.  In the event that any provision of this Agreement or the application thereof, becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force and effect and the application of such provision to other persons or circumstances will be interpreted so as reasonably to effect the intent of the Parties.  The Parties further agree to negotiate in good faith to modify this Agreement so as to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that is mutually agreeable to the Parties and that will achieve, to the extent possible, the economic, business and other purposes of such void or unenforceable provision.

 

14.          Further Assurances.  Each Party shall cooperate and take such action as may be reasonably requested by the other Party in order to carry out the provisions and purpose of this Agreement and the transaction contemplated hereby.

 

15.          Counterparts.  This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become

 

5

 

effective when one or more counterparts have been signed by each of the Parties and delivered to the other Parties, it being understood that all Parties need not sign the same counterpart.

 

16.          Notices.  All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given or made as follows: (a) if sent by registered or certified mail in the United States return receipt requested, upon receipt; (b) if sent designated for overnight delivery by nationally recognized overnight air courier (such as Federal Express), two business days after delivery to such courier; (c) if sent by electronic mail transmission before 5:00 p.m. Eastern Time, upon receipt; (d) if sent by electronic mail transmission after 5:00 p.m. Eastern Time, on the following business day; and (e) if otherwise actually personally delivered, when delivered, provided that such notices, requests, demands and other communications are delivered to the address set forth below, or to such other address as any party shall provide by like notice to the other Parties to this Agreement::

 

(1)   if to a Stockholder, to the address set forth below to its signature.

 

(2)   If to the Company, to:

 

TetraLogic Pharmaceuticals Corporation

Attention:  General Counsel

E-mail: rsherman@TLOG.com

 

with a copy (which shall not constitute notice) to:

 

Pepper Hamilton LLP
 620 Eighth Avenue
 New York, NY 10018
 Attention: Valérie Demont
 E-mail:  demontv@pepperlaw.com

 

[Signatures appear on following page]

 

6

 

IN WITNESS WHEREOF, the undersigned have duly executed and delivered this Voting Agreement as of the date first above written.

 

	
 
    	
TETRALOGIC PHARMACEUTICALS CORPORATION
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Kevin Buchi
    
	
 
    	
Name:
    	
Kevin Buchi
    
	
 
    	
Title:
    	
CEO
    

 

[Additional Signature Pages Follow]

 

 

[Signature page to Voting Agreement]

 

 

	
 
    	
STOCKHOLDERS
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
/s/ Paul Schmitt
    
	
 
    	
PAUL SCHMITT
    
	
 
    	
NUMBER OF SHARES:   30,000
    
	
 
    	
ADDRESS: 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
/s/ Andrew   Pecora
    
	
 
    	
ANDREW PECORA
    
	
 
    	
NUMBER OF SHARES:   136,176
    
	
 
    	
ADDRESS:
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
/s/ Pat   Hutchison
    
	
 
    	
PAT HUTCHISON
    
	
 
    	
NUMBER OF SHARES: 7,000
    
	
 
    	
ADDRESS: 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
/s/ Kevin Buchi
    
	
 
    	
KEVIN BUCHI
    
	
 
    	
NUMBER OF SHARES:   480,714
    
	
 
    	
ADDRESS: 
    

 

[Signature page to Voting Agreement]

 

 

	
 
    	
/s/ Richard   Sherman
    
	
 
    	
RICHARD SHERMAN
    
	
 
    	
NUMBER OF SHARES:   75,000
    
	
 
    	
ADDRESS: 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
NOVITAS CAPITAL III,   L.P
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
BY: 
    	
/s/ Paul J.   Schmitt
    
	
 
    	
NAME: PAUL SCHMITT
    
	
 
    	
TITLE: Managing   Director
    
	
 
    	
NUMBER OF SHARES:   1,512,962
    
	
 
    	
ADDRESS: 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
PECORA & CO.,   LLC
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
BY:
    	
/s/ Andrew   Pecora
    
	
 
    	
NAME: ANDREW PECORA
    
	
 
    	
TITLE: Chairman
    
	
 
    	
NUMBER OF SHARES:   48,654
    
	
 
    	
ADDRESS:
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
PFIZER INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
BY:
    	
/s/ Barbara J.   Dalton
    
	
 
    	
NAME: BARBARA J. DALTON
    
	
 
    	
TITLE: Vice President
    
	
 
    	
NUMBER OF SHARES:   1,548,241
    
	
 
    	
ADDRESS: 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
With a copy to:
    
	
 
    	
Andrew J. Muratore
    
	
 
    	
Assistant General   Counsel
    
	
 
    	
Pfizer Inc. 
    

 

[Signature page to Voting Agreement]

 

 

	
 
    	
HEALTHCARE VENTURES
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
BY:
    	
/s/ Augustine   Lawlor
    
	
 
    	
NAME: AUGUSTINE LAWLOR
    
	
 
    	
TITLE: GENERAL PARTNER
    
	
 
    	
NUMBER OF SHARES:   2,586,466
    
	
 
    	
ADDRESS:
    

 

[Signature page to Voting Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]